相似文献
1
An engineering feat of small proportions.
Transl Breast Cancer Res. 2022 Oct 31;3:35. doi: 10.21037/tbcr-22-44. eCollection 2022.
2
miR-16 promotes the apoptosis of human cancer cells by targeting FEAT.
BMC Cancer. 2015 Jun 2;15:448. doi: 10.1186/s12885-015-1458-8.
3
Immunogenic FEAT protein circulates in the bloodstream of cancer patients.
J Transl Med. 2016 Sep 22;14(1):275. doi: 10.1186/s12967-016-1034-2.
4
FEAT expression correlates with tumor size, PR status, HER2 expression, Ki67 index, and molecular subtype and predicts recurrence in breast cancer.
Neoplasma. 2017;64(1):123-130. doi: 10.4149/neo_2017_115.
5
FEAT enhances INSL3 expression in testicular Leydig cells.
Genes Cells. 2018 Nov;23(11):952-962. doi: 10.1111/gtc.12644. Epub 2018 Oct 2.
6
Flexible exoskeleton-assisted training enhances lower limb motor function after stroke: a systematic review and meta-analysis.
J Neurol. 2025 Mar 19;272(4):274. doi: 10.1007/s00415-025-12998-1.
7
A flexible symbolic regression method for constructing interpretable clinical prediction models.
NPJ Digit Med. 2023 Jun 5;6(1):107. doi: 10.1038/s41746-023-00833-8.
8
Fluorescein-enhanced autofluorescence thoracoscopy in patients with primary spontaneous pneumothorax and normal subjects.
Am J Respir Crit Care Med. 2006 Jul 1;174(1):26-30. doi: 10.1164/rccm.200602-259OC. Epub 2006 Apr 20.
9
Faculty education in addiction training (FEAT): Evaluating an online training program for multidisciplinary health professions educators.
Subst Abus. 2020;41(3):292-296. doi: 10.1080/08897077.2020.1783739.
10
Development of a food handling practices assessment tool based on the Sri Lanka food regulations.
SAGE Open Med. 2023 Sep 6;11:20503121231196009. doi: 10.1177/20503121231196009. eCollection 2023.
本文引用的文献
1
Efficacy and safety of margetuximab plus chemotherapy trastuzumab plus chemotherapy in Chinese patients with pretreated HER2-positive advanced metastatic breast cancer: results from a randomized, open-label, multicenter, phase II bridging study.
Transl Breast Cancer Res. 2022 Oct 31;3:31. doi: 10.21037/tbcr-22-35. eCollection 2022.
2
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
JAMA Oncol. 2021 Apr 1;7(4):573-584. doi: 10.1001/jamaoncol.2020.7932.
3
Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab.
Front Immunol. 2020 Jan 13;10:3069. doi: 10.3389/fimmu.2019.03069. eCollection 2019.
4
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics.
J Hematol Oncol. 2019 Sep 5;12(1):92. doi: 10.1186/s13045-019-0779-5.
5
A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors.
Theranostics. 2019 Jul 13;9(18):5412-5423. doi: 10.7150/thno.33598. eCollection 2019.
6
Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.
Blood. 2011 Sep 1;118(9):2530-40. doi: 10.1182/blood-2011-01-330357. Epub 2011 Jul 18.
7
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
J Clin Oncol. 2008 Apr 10;26(11):1789-96. doi: 10.1200/JCO.2007.14.8957. Epub 2008 Mar 17.
8
Fcgamma receptors as regulators of immune responses.
Nat Rev Immunol. 2008 Jan;8(1):34-47. doi: 10.1038/nri2206.
9
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
Nat Med. 2000 Apr;6(4):443-6. doi: 10.1038/74704.
10
Human antibodies by design.
Nat Biotechnol. 1998 Jun;16(6):535-9. doi: 10.1038/nbt0698-535.
Zotero 插件